TODD STRATEGY GROUP

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Oct 20, 2025

Bills named in this filing 2

Lobbying activity 1

Medicare/Medicaid

Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.